JWH-116

JWH-116 is a synthetic cannabinoid from the naphthoylindole family, which acts as a full agonist at both the CB₁ and CB₂ cannabinoid receptors, with a moderate selectivity for CB₂. It was discovered by and named after Dr. John W. Huffman.

Chemistry

JWH-116 is part of the Naphthoylindole family of synthetic cannabinoids. It is structurally related to other synthetic cannabinoids including JWH-018, JWH-073, and JWH-200.

Pharmacology

JWH-116 acts as a full agonist at both the CB₁ and CB₂ cannabinoid receptors. It has a moderate selectivity for the CB₂ receptor. The CB₁ receptor is primarily located in the brain, and mediates the psychoactive effects of cannabinoids. The CB₂ receptor is primarily found in the immune system, and is involved in immune response and inflammation.

Effects

The effects of JWH-116 are similar to those of other synthetic cannabinoids and include euphoria, relaxation, and altered perception. However, it can also cause adverse effects such as anxiety, paranoia, and psychosis in some users.

Legal Status

JWH-116 is illegal in many countries, including the United States, where it is classified as a Schedule I controlled substance.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• JWH-018
• JWH-073
• JWH-200

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia